Atrial Fibrillation (AF)FLASH AFNCT07779213
Detection of Atrial Fibrillation Using PPG From Smartphone Cameras
An observational study of Atrial Fibrillation (AF), run by Happitech BV at 5 sites in 2 countries.
Trial summary
The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Read more about this study
- Who is it for?
- Ages 22 minutes and older
- Conditions the study is for
- Atrial Fibrillation (AF)
- What is being tested?
- 12 Lead ECG is compared to a smartphone based PPG
- How many people
- 554 participants
- Where
- 5 sitesin 2 countries
- Study dates
- 30 Jun 2026to Nov 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 minutes and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Male and female patients aged 22 years or older who are cardiology patients consulting the cardiac outpatient clinic, 50% of whom have a rhythm of atrial fibrillation at the time of enrollment, and own a smartphone.
Who may be able to join
- Adults aged 22 years or older
- Owns a smartphone and knows how to operate and navigate different applications.
- Individuals able to read, understand, and sign the consent form.
- Cardiology patients consulting the cardiac outpatient clinic.
- History of persistent AF or other cardiac rhythm
Who cannot join
- Participants with cognitive impairments
- Individuals who cannot read, speak, and/or understand English
- Patients with implantable neurostimulators, cardiac implantable device in an atrial or ventricular paced rhythm documented on a 12-lead ECG during the initial study visit
Trial locations and contacts
5 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
5 sites in 2 countries
United States4 sites, 4 recruiting
- Recruiting
Nair Research, LLC dba Arrhythmia Research Group LLC
Jonesboro, Arkansas, 72401
Kayla Rubino, 870-340-7387, krubino@drnairresearch.com
Devi Nair, Doctor
- Recruiting
South Denver Cardiology
Littleton, Colorado, 80210
Kathy Siegel, Clinical Research Director, 720-217-6139, ksiegel@southdenver.com
Srikanth Sundaram, Doctor
- Not yet recruiting
Tulane University
New Orleans, Louisiana, 70112
Kunal Sameer, Associate Director of Ops, 203-285-5666, ksameer@tulane.edu
Nassair Marrouchi, Doctor
- Recruiting
CardioVascular Health Clinic
Oklahoma City, Oklahoma, 73134
Sophie Haynes, Regulatory Director, 405-696-0007, sophie@hightowerclinical.com
Monica Lo, Doctor
Netherlands1 site, 1 recruiting
- Recruiting
Isala Zwolle
Zwolle, Overijssel, 8025 AB
Fleur van Haveren, Research Cardiology, 088 6248377, f.van.haveren@isala.nl
Sebastien Krul, Doctor
About this study
Official title: Detection of Atrial Fibrillation Using Photoplethysmography From Smartphone Cameras
The protocol is designed to enroll patients from at least 3 diverse clinical sites with smartphones who are being evaluated for the presence or absence of atrial fibrillation (AF) using the Heart Rhythm Software algorithm running on their smartphones. Algorithm output will be compared to a gold standard of 12-lead ECG recorded with a simultaneous PPG measurement.
Read the detailed description
Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is increasing and is expected to continue increasing for decades,. Detection of AF episodes may be useful for the identification of undiagnosed AF and in making clinical management decisions that include oral anticoagulation, restoration and maintenance of sinus rhythm, control of ventricular rate, and risk factor modification. Treatment of AF is associated with improvements of quality of life, stroke prevention, and reduced risk of heart failure.
Traditionally, diagnosis of AF is done using an electrocardiogram, with low amplitude or absent p-waves and narrow complex "irregularly irregular" pattern intervals seen on the ECG,. After diagnosis, there are a variety of methods that can be used to manage AF. Ambulatory ECG monitoring, implantable monitoring devices, and over-the-counter wrist-worn devices have been used to manage patients with AF,,. However, these devices are inconvenient and expensive which limits their wide adoption into clinical practice. There is an unmet clinical need for an easy to use and inexpensive over-the-counter FDA-cleared products that can detect episodes of AF in real-time and notify patients to seek out further care when AF is suspected.
Recent technological advancements have allowed for the identification of AF using smartwatches, with device manufacturers gaining over-the-counter regulatory clearance for their irregular heart rate detection algorithms,. These wrist-worn devices use a light-based measurement method called photoplethysmography (PPG) to measure changes in light absorbance and reflectance to understand changes in blood flow in superficial vasculature. The waveform generated from this measurement can be used to measure parameters like pulse rate, respiratory rate, pulse rate variability and others in addition to detecting AF. The increasing ubiquity of smartphones worldwide has led to greater availability of heart rhythm diagnostics using smartphone photoplethysmography (PPG). Smartphone camera PPG technology uses the light-emitting diode in cameras to measure pulsatile changes in light intensity that are reflected from a finger and can be used to detect AF. The widespread availability of this technology has the potential to improve the accessibility and convenience of heart rhythm monitoring, particularly in remote or underserved areas. This could result in improvements in early detection and management of AF, leading to better patient outcomes. Several smartphone PPG-based algorithms have been developed that utilize smartphones' built-in cameras to detect AF. The sensitivity and specificity of these algorithms for the detection of AF range between 81%-100% and 85%-100% respectively. However, there is a lack of evidence regarding the performance of these algorithms in detecting AF in an out-of-hospital setting using a gold-standard reference.
Happitech has developed a proprietary software development kit (SDK) that can be utilized to measure patients' cardiovascular parameters and identify potential pathologies including AF. Happitech's algorithm requires users to place a digit directly against their phone camera, and the camera and underlying algorithm detect subtle differences in blood flow to calculate physiological parameters for monitoring and clinical use.
The purpose of this study is to validate the performance of Happitech's PPG-based algorithm for the detection of AF against a 12-lead ECG in a diverse population of patients including cardiology patients being evaluated as inpatients or at a cardiology clinic visit.
- Conditions
- Atrial Fibrillation (AF)
- Being tested
- 12 Lead ECG is compared to a smartphone based PPG
- Keywords
- wearables, smartphone based ppg, ppg, digital health, health equity, atrial fibrillation, healthtech, cardiac monitoring
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
12 Lead ECG is compared to a smartphone based PPGDiagnostic test
12 Lead ECG is compared to a smartphone based PPG
| Study group | Role | What they receive |
|---|---|---|
| Sinus Rhythm | Patient visiting the Cardiology Clinic in Sinus Rhythm Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG | |
| Atrial Fibrillation | Patient visiting the Cardiology Clinic in Atrial Fibrillation Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG | |
| Other | Patient visiting the Cardiology Clinic with neither Sinus Rhythm or Atrial Fibrillation Receives: Diagnostic Test: 12 Lead ECG is compared to a smartphone based PPG |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the sensitivity and specificity of the Heart Rhythm Software
To evaluate the sensitivity and specificity of the Heart Rhythm Software algorithm running on a commercially available smartphone to detect atrial fibrillation segments using photoplethysmography (PPG) as measured through the phone's camera.
Se is defined as the percentage of patients with 90 second interval recordings scored by the Heart Rhythm Software algorithm as AF, out of all intervals determined by the Clinical Adjudication Committee (CAC) to be AF (gold standard).
Sp is defined as the percentage of patients with 90 second intervals scored by the Heart Rhythm Software algorithm as NSR out of all ECG recordings determined by the CAC to be NSR.
Measured: Through study completion, an average of 6 months
Secondary outcomes (1)
Sensitivity & Specificity across subgroups
The accuracy of the Happitech Heart Rhythm Software algorithm in detecting irregular rhythm suspected of AF and regular rhythm suspected normal sinus rhythm will be further investigated in subgroups defined by ethnicity, race, BMI, age group, smartphone type, and Fitzpatrick scale score. The sensitivity and specificity will be presented as an estimate and associated 95% CI's, as well as a Chi-square or Fisher's Exact p-value to assess if all levels of the subgroup are homogeneous.
Measured: through study completion, an average of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start30 Jun 2026
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 554 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Happitech BV
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07779213
- Sponsor's protocol ID
- HAPP-CTP-FDA-2025-002
- Acronym
- FLASH AF
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided